[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
스폰서배너광고 안내  배너1 배너2 배너3
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
이승환 (Seung-Whan Lee) 저자 이메일 보기
울산대학교 의과대학, 서울아산병원
조회 335  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion
열기 Authors and Affiliations


Procedural results for percutaneous coronary intervention (PCI) in coronary vessels with chronic total occlusion (CTO) have improved in recent years, and PCI strategies have moved toward more complete revascularization with more liberal use of CTO-PCI. However, evidence evaluating CTO-PCI is limited to observational studies and small clinical trials.

In this open-label, multicenter, randomized, noninferiority trial, PCI-eligible patients were assigned to receive either 1 of 2 strategies: PCI or no PCI for the qualifying de novo CTO lesion with the option for PCI of obstructive non-CTO lesions at the discretion of the operator. The primary end point was a composite of death, myocardial infarction, stroke, or any revascularization. Health-related quality of life was assessed at baseline and at 1, 6, 12, 24, and 36 months. Because of slow recruitment, the trial was stopped before completion of the 1284 planned enrollments.

Between March 2010 and September 2016, 834 patients were randomly assigned to the CTO-PCI (n=417) or no CTO-PCI (n=398) strategy. Among the patients assigned to the no CTO-PCI strategy, 78 (19.6%) crossed over to receive staged CTO-PCI within 3 days of randomization. The overall CTO-PCI success rate was 90.6%. Serious nonfatal complications associated with CTO-PCI occurred in 3 patients (1 stroke, 1 cardiac tamponade, and 1 patient with recurrent episodes of ventricular tachyarrhythmia induced by intracoronary thrombus). Approximately half of the patients in each group underwent PCI for an average of 1.3 non-CTO lesions, resulting in a comparable residual SYNTAX score (Synergy Between PCI With TAXUS and Cardiac Surgery; 3.7±5.4 versus 4.0±5.9, P=0.42) confined to non-CTO vessels. During a median follow-up of 4.0 years (interquartile range, 2.4 to 5.1 years), there was no significant difference between the CTO-PCI and the no CTO-PCI strategies in the incidence of the primary end point (22.3% versus 22.4%, hazard ratio, 1.03; 95% CI, 0.77 to 1.37; P=0.86). Both CTO-PCI and no CTO-PCI strategy were associated with significant improvements but without between-group differences in disease-specific health status that was sustained through 36 months.

CTO-PCI was feasible with high success rates. There was no difference in the incidence of major adverse cardiovascular events with CTO-PCI versus no CTO-PCI, but the study was limited by low power for clinical end points and high crossover rates between groups.

- 형식: Research article
- 게재일: 2019년 02월 (BRIC 등록일 2019-04-10)
- 연구진: 국내연구진태극기
- 분야: Medicine
  댓글 0
이승환 님 전체논문보기 >
김원장 (울산의대, 서울아산병원)
박덕우 (울산의대, 서울아산병원)
박성욱 (울산의대, 서울아산병원)
박승정 (울산의대, 서울아산병원)
이필형 (울산대학교 의과대학, 서울아...)
관련분야 논문보기

Google (by Seung-Whan Lee)
Pubmed (by Seung-Whan Lee)
프리미엄 Bio일정 Bio일정 프리미엄 안내
BRIC X ThermoFisher Scientific과 함께하는 사이언스 바캉스
BRIC X ThermoFisher Scientific과 함께하는 사이언스 바캉스
사전접수: ~2019.07.26
날짜: 2019.08.07~08
장소: 강남구 광평로 281, 수서오피스빌딩 11층 (수서역 3번 출구)
2019 부산대학교 의학전문대학원 의과학과 Open Lab
2019 부산대학교 의학전문대학원 의과학과 Open Lab
사전접수: ~2019.08.20
날짜: 2019.08.29
장소: 부산대학교 의학전문대학원(양산캠퍼스) 통합행정동 116호
[대졸자 대상]바이오QC 실무과정 7기 모집
[대졸자 대상]바이오QC 실무과정 7기 모집
날짜: 2019.09.02~06.12
장소: 성남시 분당구 황새울로 329번길 5
(고용부 재직자 무료과정)바이오/의약분야 계약 및 협상의 이해과정
(고용부 재직자 무료과정)바이오/의약분야 계약 및 협상의 이해과정
날짜: 2019.07.24~26
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실
생물정보 빅데이터 분석 UCC 공모전
생물정보 빅데이터 분석 UCC 공모전
날짜: 2019.08.22
주관: K-Genome 유전체빅데..
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS